Download PDF
Endoscopy 2008; 40(9): 711-716
DOI: 10.1055/s-2008-1077502
Original article

© Georg Thieme Verlag KG Stuttgart · New York

Low incidence of adenocarcinoma and high-grade intraepithelial neoplasia in patients with Barrett’s esophagus: a prospective cohort study

J.  Martinek1 , M.  Benes1 , P.  Brandtl1 , T.  Hucl1 , M.  Vasicek1 , L.  Voska2 , V.  Lanska3 , V.  Nosek1 , J.  Spicak1
  • 1Department of Hepatogastroenterology, IKEM (Institute for Clinical and Experimental Medicine), Prague, Czech Republic
  • 2Department of Clinical and Transplant Pathology, IKEM (Institute for Clinical and Experimental Medicine), Prague, Czech Republic
  • 3Department of Biostatistics, IKEM (Institute for Clinical and Experimental Medicine), Prague, Czech Republic
Further Information

Publication History

submitted 23 October 2007

accepted after revision 16 June 2008

Publication Date:
12 August 2008 (online)

Also available at
    Permissions and Reprints

See also:

Commentaire de travail de J. Martinek et al., pp. 711Endoscopy 2008; 40(09): 967-967
DOI: 10.1055/s-0032-1306864

Background and study aims: Barrett’s esophagus is a premalignant condition. The risk of developing high grade intraepithelial neoplasia (HGIN) or adenocarcinoma is currently a matter of debate. Due to several shortcomings, previous studies have probably overestimated the risk. The main aim of our study was to investigate the incidence of HGD and adenocarcinoma in a cohort of patients with Barrett’s esophagus.

Patients and methods: In a prospective, cohort study, all patients had intestinal metaplasia and macroscopic evidence of short- or long-segment (< 3 cm or ≥ 3cm) Barrett’s esophagus. All patients underwent a standard protocol including regular endoscopies with biopsies and were treated with a proton pump inhibitor or antireflux surgery.

Results: A total of 135 patients underwent 623 endoscopies during 700 patient-years (mean follow-up 5.2 ± 2.3 years). Simultaneous HGIN and adenocarcinoma were detected in two patients with long-segment Barrett’s esophagus (1.5 %; 2 and 6 years after the index endoscopy). Low grade intraepithelial neoplasia (LGIN) was detected in 25 patients (18.5 %); in 11 of these patients (44 %), LGIN was not confirmed in later biopsies. Our study shows an incidence of HGIN/adenocarcinoma of 1/350 patient-years. Endoscopic regression of Barrett’s esophagus was seen in 20.7 % of patients.

Conclusion: The incidence of HGIN/adenocarcinoma is low in patients with adequately treated Barrett’s esophagus. The annual risk of developing HGIN/adenocarcinoma is 0.21 % (1.6 % in long-segment Barrett’s esophagus).

References

  • 1 Westhoff B, Brotze S, Weston S. et al . The frequency of Barrett’s esophagus in high-risk patients with chronic GERD.  Gastrointest Endosc. 2005;  61 226-231
    CrossrefPubMedGoogle Scholar
  • 2 Boyer J, Laugier R, Chemali M. et al . French Society of Digestive Endoscopy SFED guideline: monitoring of patients with Barrett’s esophagus.  Endoscopy. 2007;  39 840-842
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Ell C, May A, Gossner L. et al . Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett’s esophagus.  Gastroenterology. 2000;  118 670-677
    CrossrefPubMedGoogle Scholar
  • 4 Bartelsman J F, Hameeteman W, Tytgat G N. Barrett’s esophagus.  Eur J Cancer Prev. 1992;  1 323-325
    CrossrefPubMedGoogle Scholar
  • 5 Achkar E, Carey W. The cost of surveillance for adenocarcinoma complicating Barrett’s esophagus.  Am J Gastroenterol. 1988;  83 291-294
    PubMedGoogle Scholar
  • 6 Cameron A J, Ott B J, Payne W S. The incidence of adenocarcinoma in columnar lined (Barrett’s) esophagus.  N Engl J Med. 1985;  313 857-859
    CrossrefPubMedGoogle Scholar
  • 7 Csendes A, Braghetto I, Brudiles P. et al . Long-term results of classic anti-reflux surgery in 152 patients with Barrett’s esophagus: clinical, radiologic, endoscopic, manometric, and acid reflux test analysis before and late after operation.  Surgery. 1998;  126 645-657
    PubMedGoogle Scholar
  • 8 Drewitz D J, Sampliner R E, Garewal H S. The incidence of adenocarcinoma in Barrett’s esophagus: a prospective study of 170 patients followed 4.8 years.  Am J Gastroenterol. 1997;  92 212-215
    PubMedGoogle Scholar
  • 9 Ferraris R, Bonelli L, Conio M. et al . Incidence of Barrett’s adenocarcinoma in an Italian population: an endoscopic surveillance programme.  Eur J Gastroenterol Hepatol. 1997;  9 881-885
    CrossrefPubMedGoogle Scholar
  • 10 Hameeteman W, Tytgat G N, Houthoff H J. et al . Barrett’s esophagus: development of dysplasia and adenocarcinoma.  Gastroenterology. 1989;  96 1249-1256
    CrossrefPubMedGoogle Scholar
  • 11 Williamson W A, Ellis F HJ, Gibb S P. et al . Barrett’s esophagus. Prevalence and incidence of adenocarcinoma.  Arch Intern Med. 1991;  151 2212-2216
    CrossrefPubMedGoogle Scholar
  • 12 Cooper B T, Chapman W, Neumann C S. et al . Continuous treatment of Barrett’s esophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.  Aliment Pharmacol Ther. 2006;  23 727-733
    CrossrefPubMedGoogle Scholar
  • 13 Conio M, Blanchi S, Lapertosa G. et al . Long-term endoscopic surveillance of patients with Barrett’s esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study.  Am J Gastroenterol. 2003;  98 1931-1939
    CrossrefPubMedGoogle Scholar
  • 14 Sharma P, Falk G W, Weston A P. et al . Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus.  Clin Gastroenterol Hepatol. 2006;  4 566-572
    CrossrefPubMedGoogle Scholar
  • 15 Gladman L, Chapman W, Iqbal T H. et al . Barrett’s esophagus: an audit of surveillance over a 17-year period.  Eur J Gastroenterol Hepatol. 2006;  18 271-276
    CrossrefPubMedGoogle Scholar
  • 16 Shaheen N J, Crosby M A, Bozymski E M. et al . Is there publication bias in the reporting of cancer risk in Barrett’s esophagus?.  Gastroenterology. 2000;  119 333-338
    CrossrefPubMedGoogle Scholar
  • 17 El-Serag H B, Aguirre T V, Davis S. et al . Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus.  Am J Gastroenterol. 2004;  99 1877-1883
    CrossrefPubMedGoogle Scholar
  • 18 Hillman L C, Chiragakis L, Shadbolt B. et al . Proton pump inhibitor therapy and the development of dysplasia in patients with Barrett’s esophagus.  Med J Austr. 2004;  180 387-391
    PubMedGoogle Scholar
  • 19 Sharma P, McQuaid K, Dent J. et al . A critical review of the diagnosis and the management of Barrett’s esophagus: The AGA Chicago Workshop.  Gastroenterology. 2004;  127 310-330
    CrossrefPubMedGoogle Scholar
  • 20 Valkil N, van Zanten S V, Kahrilas P. et al . The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus.  Am J Gastroenterol. 2006;  101 1900-1920
    CrossrefPubMedGoogle Scholar
  • 21 Wang K K, Wongkeesong M, Buttar N S. AGA technical review on the role of the gastroenterologist in the management of esophageal carcinoma.  Gastroenterology. 2005;  128 1471-1505
    CrossrefPubMedGoogle Scholar
  • 22 Provenzale D, Schmitt C, Wong J B. Barrett’s esophagus: a new look at surveillance based on emerging estimates of cancer risk.  Am J Gastroenterol. 1999;  94 2043-2053
    CrossrefPubMedGoogle Scholar
  • 23 Ell C, May A, Pech O. et al . Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer).  Gastrointest Endosc. 2007;  65 3-10
    CrossrefPubMedGoogle Scholar
  • 24 Lim C H, Treanor D, Dixon M F, Axon A TR. Low-grade dysplasia in Barrett’s esophagus has a high risk of progression.  Endoscopy. 2007;  39 581-587
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Rex D K, Cummings O W, Shaw M. et al . Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn.  Gastroenterology. 2003;  125 1670-1677
    CrossrefPubMedGoogle Scholar
  • 26 Gerson L B, Shetler K, Triadafilopoulos G. Prevalence of Barrett’s esophagus in asymptomatic individuals.  Gastroenterology. 2002;  123 461-467
    CrossrefPubMedGoogle Scholar
  • 27 Edelstein Z R, Farrow D C, Bronner M P. et al . Central adiposity and risk of Barrett’s esophagus.  Gastroenterology. 2007;  133 403-411
    CrossrefPubMedGoogle Scholar
  • 28 Vicari J J, Peek R M, Falk G W. et al . The seroprevalence of Cag-A positive H. pylori strains in the spectrum of gastro-esophageal reflux disease.  Gastroenterology. 1998;  115 50-57
    CrossrefPubMedGoogle Scholar

J. Martinek, MD, PhD 

Department of Hepatogastroenterology
IKEM

Videnska 1958/9
140 21 Praha 4
Czech Republic

Fax: +420-261-362615

Email: jan.martinek@volny.cz

      >